Page last updated: 2024-09-03

pramipexole and Nerve Degeneration

pramipexole has been researched along with Nerve Degeneration in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	6 (75.00)	29.6817
2010's	1 (12.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cho, JH; Kim, GS; Kim, MK; Park, HS; Won, C	1
Ariga, H; Inden, M; Kitamura, Y; Shibaike, T; Taira, T; Takata, K; Tamaki, A; Taniguchi, T; Yamamoto, A; Yanagida, T; Yasui, H	1
Bergmans, P; Booij, J; Stoof, JC; van Royen, EA; Winogrodzka, A; Wolters, EC	1
Fleckenstein, AE; Hanson, GR; Rau, KS; Truong, JG	1
Anderson, DW; Bradbury, KA; Schneider, JS	1
Althaus, JS; Andrus, PK; Hall, ED; Oostveen, JA; VonVoigtlander, PF	1
Carvey, PM; Chen, EY; Ling, ZD; Lipton, JW; Ma, SY; Robie, HC; Tong, CW; Vu, TQ	1

Trials

1 trial(s) available for pramipexole and Nerve Degeneration

Article	Year
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 2002, Apr-03, Volume: 287, Issue:13 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain; Cocaine; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Regression Analysis; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2002

Article

Year

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

JAMA, 2002, Apr-03, Volume: 287, Issue:13

Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain; Cocaine; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Regression Analysis; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2002

Other Studies

7 other study(ies) available for pramipexole and Nerve Degeneration

Article	Year
Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine. Neuroreport, 2015, Jan-21, Volume: 26, Issue:2 Topics: Animals; ATPases Associated with Diverse Cellular Activities; Benzothiazoles; Cells, Cultured; Dopamine Agonists; Dopaminergic Neurons; Metalloendopeptidases; Mice; Mice, Inbred ICR; Nerve Degeneration; Neuroprotective Agents; Oxidopamine; Pramipexole; Receptors, Dopamine D2; Signal Transduction	2015
Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochemistry international, 2009, Volume: 55, Issue:8 Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Corpus Striatum; Cytochromes c; Dopamine; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Hydroxyl Radical; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neural Pathways; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Rotenone; Substantia Nigra; Uncoupling Agents	2009
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2003, Volume: 74, Issue:3 Topics: Antiparkinson Agents; Benzothiazoles; Caudate Nucleus; Cocaine; Corpus Striatum; Disease Progression; Female; Humans; Male; Nerve Degeneration; Parkinson Disease; Pergolide; Pramipexole; Putamen; Radiopharmaceuticals; Receptors, Dopamine D2; Reproducibility of Results; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2003
Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. European journal of pharmacology, 2003, Aug-08, Volume: 474, Issue:2-3 Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Neuropeptides; Parkinson Disease; Pramipexole; Rats; Rats, Sprague-Dawley; Synaptic Vesicles; Thiazoles; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins	2003
Neuroprotection in Parkinson models varies with toxin administration protocol. The European journal of neuroscience, 2006, Volume: 24, Issue:11 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, Nuclear; Axons; Benzothiazoles; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Niacinamide; Parkinsonian Disorders; Pramipexole; Substantia Nigra; Tyrosine 3-Monooxygenase	2006
Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain research, 1996, Dec-02, Volume: 742, Issue:1-2 Topics: Animals; Benzothiazoles; Brain Ischemia; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Gerbillinae; Male; Methamphetamine; Nerve Degeneration; Pramipexole; Substantia Nigra; Thiazoles	1996
Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine. Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:2 Topics: Animals; Benzothiazoles; Cell Count; Cell Death; Dopamine; Dopamine Agonists; Male; Neostriatum; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles	2000